期刊文献+

实验研究不同厂家注射用加替沙星的产品质量

Experimental studies about quality of products of Gatifloxacin for Injection produced by different pharmaceutical manufactures
下载PDF
导出
摘要 目的:研究不同厂家注射用加替沙星的产品质量,为医院提供用药参考。方法:采用HPLC法测定几家注射用加替沙星的含量和有关物质;观察其在40℃RH75%6个月和室温(10-35℃)留样12个月的产品稳定性;根据《中国药典》评价产品质量。结果:采用HPLC法在293nm波长处测定其含量和有关物质,在5.0-80.0μg/ml范围内浓度与其峰面积呈良好的线性关系(r=0.9996);在各项专属性试验中,加替沙星与其他杂质峰基线均分离良好,有关物质检测限为5ng(S/N=3);4家产品均稳定,有效期在2年以上。结论:4家注射用加替沙星产品质量均符合《中国药典》(二部)2000年版和2005年版的要求。 Objective:To study the qualities of Gatifloxacin for Injection produced by different phamaceutical manufacturers in order to provide references to hospitals for application. Methods: HPLC was used to determine the content of gatifloxacin and related substances in the Gatifloxacin for Injection; to investigate the stabitity of Gatifloxacin for Injection from different manufactures at 40℃ RH75% 6 months and at 10-35℃ 12 months; to evaluate the quality of products about injection by the Chinese Pharmacopeia. Results: The content of gatifloxacin and related substances were determined by HPLC at 293 nm. The detectable concentration of gatifloxacin showed a good linear correlation in the range of 5.0-80.0μg/ml, r=0.999 6. All the chief peaks of gatifloxacin and those of their related substances could be well isolated in all the specificity test and the detective limit was 5 ng (S/N=3). Products from these 4 manufacturers presented a stable state with a validity time all over 2 years. Conclusion: Quality of products manufactured by 4 manufacturing factories all accord with requirements of the Chines Pharmacopeia (the second part) of 2000 and 2005 edition.
出处 《中国医药导报》 CAS 2008年第20期33-35,共3页 China Medical Herald
关键词 高效液相色谱法 不同厂家 注射用加替沙星 产品质量 HPLC Different manufactures Gatifloxacin for Injection Quality of products
  • 相关文献

参考文献5

  • 1[1]Gatifloxacin(Tequin)[Package insert].Princeton(NJ):Bristol-Myers squibb[Z].2003.
  • 2[2]Blondeau JM,Borsos S,Hesje CK Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicilin-resistant staphylococcus aureus[J]J Chemother,2007,19(2):146-151.
  • 3[3]Nicholson SC,Wilson WR,Naughton BJ,et of.Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia[J].Diagn Microbial Infect Dis,2002,44:117-125.
  • 4朱曼,王睿.第四代氟喹诺酮类抗菌药——加替沙星[J].中国临床药理学与治疗学,2001,6(4):377-381. 被引量:71
  • 5[5]Dalhoff A,Schmity FJ.In vitro antibacterial activity and pharnmaodynamics of new quinolones[J].Eur J Clin Microbial Infect Dis,2003,22:203-221.

二级参考文献21

  • 1赵树清,王金生.新型氟喹诺酮抗菌剂——AM—1155[J].中国医药情报,1996,2(4):249-252. 被引量:4
  • 2JLM. Oral and iv formulations of gatifoxacin cleared for US. market. Am J Health-Syst Pharm, 2000; 57:204
  • 3Hosaka M, Kinoshita S, Toyama A, et al. Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J Antimicrob Chemther,1995; 36:293
  • 4Tomioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin and ofloxacin. Antimicrob Agents Chemother, 1993;37:1259
  • 5Takei M, Fukuda H, Yasue T, et al. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian typeⅡ topoisomerase. Antimicro Agents Chemother, 1998;42:2678
  • 6Wakabayshi E, Mitsuhashi S. In vitro antibacterial activitiy of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother, 1994;38:594
  • 7Fukuda H, Hori S, Hiramatsu K. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone- resistants mutants and the norA transformant of staphylococcus aureus. Antimicrob Agents Chemother, 1998;42:1917
  • 8Deguchi T, Yasuda M, Nakano M, et al. Comparision of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. Chemotherapy, 1997;43:239
  • 9Appelbaum PC. Quinolone activity against anaerobes. Drugs, 1999;58 (suppl 2):60
  • 10Ednie LM, Jacobs M, Appelaum PC. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother, 1998;42:2459

共引文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部